Return to Main Site 617-919-3019
401 Park Drive, 7th Floor East, Boston, MA 02215

TIDO Technology Search



Invention Type

Diagnostic/Prognostic
Information Technology/Software
Medical Device
Other
Research Tool
Therapeutics

Research Area

Allergy/Respiratory/Pulmonary Disease
Anesthesia
Audiology
Cardiovascular/Cardiology
Degenerative Disease
Dermatology
Endocrinology
Gastrointestinal/Nutrition
Genetic Disease
Health Care Management
Immunology
Infectious Disease
Inflammation
Internal Medicine
Metabolic Disease
Musculoskeletal
Neonatology/Pediatric
Neurology/Neuroscience
Oncology/Hematology
Ophthalmology
Orthopedics
Otolaryngology/Audiology
Pain
Pathology
Personalized Medicine
Psychiatric Disease
Radiology
Regenerative Medicine
Reproduction/Ob-Gyn
Stem Cell
Surgery/Wound Healing
Urology
CMCC 1595

A small molecule drug as a topical treatment for small fiber peripheral neuropathy

Inventors: Gabriel Corfas, Joshua Murtie

Invention Types: Therapeutics

Research Areas: Endocrinology, Neurology/Neuroscience

Keywords: Drug Discovery, Drug Screening, Small Molecule/Drug

For More Information Contact:  Caron, Connie

 

Invention Description:

A small molecule that enhances ligand-induced signaling by the Glial Derived Neurotrophic Factor receptor (GFR-alpha/RET) family, which when applied topically in mouse models of small fiber peripheral neuropathy prevents nerve degeneration and preserves sensory function.

Applications:

Peripheral neuropathy is very prevalent and can be caused by many diseases and disorders. Applications include neuropathies caused by:|

• Chemotherapy

• Cancer

• Lupus

• Diabetes

• Shingles

• Alcoholism

Competitive Advantages:

There are no products currently available to directly treat the underlying causes of nerve damage; the current treatments (antidepressants, anticonvulsants, lidocaine patches) only alleviate the symptoms but do not treat the associated nerve damage or address the disease that has neuropathy as a side effect. The topical use is expected to be safer and have fewer side effects than the oral administration.

Business Opportunity:

• Exclusive License

• Partnerships for Development

Key Publications: Manuscript in press (PNAS)

Related Publications: Roy K, Murtie JC, El-Khodor BF, Edgar N, Sardi SP, Hooks BM, Benoit-Marand M, Chen C, Moore H, O'Donnell P, Brunner D, Corfas G. Loss of erbB signaling in oligodendrocytes alters myelin and dopaminergic function, a potential mechanism for the pathogenesis of neuropsychiatric disorders, Proc Natl Acad Sci USA 2007; 104: 8131-8136.

IPStatus: Patented